| Bio: |
Thus, the rates of underdiagnosis could be reduced and the possibility of appropriate care could be increased.
Unfortunately, underdiagnosis is quite common;
it is possible that only 10% of cases are diagnosed.
It results from different mutations in the SERPINA1 gene, leading to changes in the AAT glycoprotein, which can alter its concentration,
conformation, and function. This may one day help them find ways to treat and prevent diseases.
Researchers from participating institutions use the database to
search for and invite patients or healthy volunteers
who meet their study criteria to participate. People participate in clinical
trials for many reasons.
In the 13 years that intravenous AAT replacement therapy
has been employed at the Hospital Regional da Asa Norte in Brasília, in 8-12
patients per week, there has never been an anaphylactic reaction. A real loss
of lung function is defined on the basis of the change over a three-year period, a decline in FEV1 ≥ 100 mL/year being considered excessive and an indication for the initiation of
specific therapy.5,11,13,101 Some patients present
emphysema on chest CT without airflow limitation on spirometry, demonstrating that chest CT is more sensitive,
at least initially, than is a functional assessment. Some guidelines,
such as those developed in Belgium,101 Portugal,13 Poland,102 and
Canada,103 have introduced the drop in FEV1 (% of predicted) after bronchodilator use as a criterion for initiating treatment in patients with AATD, although the drop in FEV1 currently has less sensitivity than does the
decrease in lung density. Studies on the rate of decline in lung density indicate that this tool is useful in helping to assess
the results of replacement therapy. However,
there is still a need to improve the biomarkers
of emphysema progression and of the response to replacement therapy.
More invasive approaches like lung volume reduction surgery (LVRS) can be offered; LVRS has demonstrated benefits in AATD, hack.allmende.io but it
seems to be inferior when compared with usual COPD, since it
has a higher short-term mortality56. Although dosage has been established at 60 mg/kg/week, it has been proposed that
doubling the dosage (120 mg/kg/week) could be even more beneficial because it leads to
serum trough AAT levels at physiologic values. In several European countries, health authorities have funded AT despite a
lack of evidence of benefit in PiSZ patients. Nevertheless, PR has improved health status,
exercise tolerance, and quality of life, all problems that AATD patients experience, thus is reasonable to recommend.
Clinical benefits of pulmonary rehabilitation (PR) have been questioned
in AATD patients, as unfavorable muscle response to
exercise has been proposed60. Influenza and pneumococcal vaccination should occur, as AATD
patients have a high susceptibility for lower
respiratory tract infections44,56,59. We might speculate that
there would be the same effect on AATD patients with COPD, although data are lacking in this area.
Values below 110 mg/dL indicate the possibility of a mutant
allele (S, Z, or a rare one) and serve as a guide to continue investigating the
genotype. Treatment with AAT replacement has shown excellent results, with rapid clinical responses, and should
be used in cases refractory to other therapies.69 Although transient hepatic elastography is useful to rule out advanced
fibrosis (stages 3 and urlscan.io 4), it is less effective in the early stages.62 In patients
with altered enzymes, cirrhosis, kjer-bendixen-4.technetbloggers.de or portal hypertension, liver ultrasound every
six months is indicated in order to screen for hepatocellular carcinoma.65 Liver disease has
a bimodal age distribution, with the first peak in early childhood and the second in individuals over
50 years of age.57 In the neonatal period, prolonged
cholestasis is the main clinical manifestation. Its prevalence varies greatly among studies, ranging from 26% to
52% in the studies with the largest patient samples,
although the presence of bronchiectasis without emphysema should not rule out a
diagnosis of AATD.54
Some people with Alpha-1 never have symptoms or related organ damage, especially if
they never smoke. You should also avoid medications that can cause liver damage.
Alcohol can increase your chances of liver damage. |
